Nikko资产管理公司报告财务损失时, Nikko 资产管理公司削减了对Ionis制药公司的股权。 Nikko Asset Management cuts stake in Ionis Pharmaceuticals as the company reports financial losses.

Nikko资产管理美洲公司将其在Ionis制药公司的股权减少了20.1%,出售39 457股,现在拥有156 657股,价值547万美元。 Nikko Asset Management Americas Inc. has reduced its stake in Ionis Pharmaceuticals by 20.1%, selling 39,457 shares, and now owns 156,657 shares worth $5.47 million. Ionis制药公司报告,其最近季度的股本净利润为64.25%,负回报率为100.05%。 Ionis Pharmaceuticals reported a negative net margin of 64.25% and negative return on equity of 100.05% in its latest quarter. 该公司提供脊椎肌肉萎缩、遗传性肾上腺质疏松症和微血糖综合症的治疗。 The company offers treatments for spinal muscular atrophy, hereditary amyloidosis, and chylomicronemia syndrome. 分析员预测,本年度公司将按每股3.5美元的收入计算。 Analysts predict the company will post -3.5 earnings per share for the current year.